Ki11502 inhibits the proliferation of EOL-1 tumor xenografts in SCID mice. EOL-1 cells were injected subcutaneously into SCID mice. After EOL-1 cells formed palpable tumors, mice were randomized into 2 groups (n = 3) and treatment was initiated. Ki11502 (50 mg/kg) was orally administered twice a day for 5 days. Control mice received diluent only. Tumors were measured twice a week. Each point represents the mean plus or minus SE of 3 tumors. Body weight of mice was measured twice a week and shown at the top.